Galeterone is a CYP17 Inhibitor for Prostate Cancer Research
Galeterone (TOK-001) is a multifunctional antiandrogen and CYP17 inhibitor for castration resistant prostate cancer (CRPC) research.
Galeterone (TOK-001) is a multifunctional antiandrogen and CYP17 inhibitor for castration resistant prostate cancer (CRPC) research.
Prostate cancer (PCa) is one of the most prevalent malignancies in the world. Depending on the grade of cancer, a variable percentage of these patients experience progression to castration-resistant prostate…
EPI-7170, a Ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist. It blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 (0-12 μM, 24 or 48…
The androgen receptor (AR) is a type of nuclear receptor and a modular steroid hormone receptor transcription factor. Specifically, the androgen receptor is activated by binding any of the androgenic…
Fatty acid synthase (FASN) is a multi-enzyme protein that catalyzes the synthesis of fatty acids. Its main function is to catalyze the synthesis of palmitate (C16:0) from acetyl CoA and…
Prostate cancer arises as an androgen driven disease. Therefore the mainstay of systemic therapy for patients with advanced disease is androgen deprivation therapy. Despite of significant responses, nearly all patients…